sodium phosphate, monobasic, monohydrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4295 10049-21-5

Description:

MoleculeDescription

Synonyms:

  • sodium phosphate, monobasic, monohydrate
  • phosphoric acid, monosodium salt, monohydrate
  • monobasic sodium phosphate monohydrate
  • monosodium phosphate monohydrate
  • Molecular weight: 137.99
  • Formula: H4NaO5P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 2000 FDA SALIX PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute phosphate nephropathy 66.37 34.91 7 563 15 63488437
Nephropathy 63.30 34.91 14 556 6327 63482125
Nephrocalcinosis 45.81 34.91 8 562 1070 63487382
Acute kidney injury 41.66 34.91 27 543 263388 63225064

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute phosphate nephropathy 61.22 30.15 7 723 38 79743620
Nephropathy 57.01 30.15 14 716 9724 79733934
Nephrocalcinosis 42.99 30.15 8 722 1494 79742164

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia indication 4996001
Urinary tract infectious disease indication 68566005
Incomplete passage of stool indication 249515001
Calcium renal calculus indication 427649000
Osteopenia of prematurity off-label use 276703007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020416 VUID
N0000148206 NUI
4018699 VANDF
4020416 VANDF
C0724635 UMLSCUI
CHEBI:114249 CHEBI
CHEMBL1368 ChEMBL_ID
593YOG76RN UNII
516949 PUBCHEM_CID
221125 RXNORM
5132 MMSL
5470 MMSL
5481 MMSL
007398 NDDF
733770001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
URELLE HUMAN PRESCRIPTION DRUG LABEL 5 0037-6321 TABLET 40.80 mg ORAL Unapproved drug other 12 sections
URIBEL HUMAN PRESCRIPTION DRUG LABEL 5 0076-0111 CAPSULE 40.80 mg ORAL unapproved drug other 20 sections
Phosphasal HUMAN PRESCRIPTION DRUG LABEL 5 0076-0902 TABLET 40.80 mg ORAL unapproved drug other 20 sections
Ustell HUMAN PRESCRIPTION DRUG LABEL 5 0076-0903 CAPSULE 40.80 mg ORAL unapproved drug other 20 sections
URIBEL HUMAN PRESCRIPTION DRUG LABEL 5 0178-0740 CAPSULE 40.80 mg ORAL unapproved drug other 21 sections
URIBEL HUMAN PRESCRIPTION DRUG LABEL 5 0178-0740 CAPSULE 40.80 mg ORAL unapproved drug other 21 sections
Sodium Phosphates Human prescription drug label 2 0409-7391 INJECTION, SOLUTION 276 mg INTRAVENOUS NDA 15 sections
Sodium Phosphates Human prescription drug label 2 0409-7391 INJECTION, SOLUTION 276 mg INTRAVENOUS NDA 15 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 130 mg ORAL unapproved drug other 19 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 130 mg ORAL unapproved drug other 19 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 130 mg ORAL unapproved drug other 19 sections
K Phos Neutral HUMAN PRESCRIPTION DRUG LABEL 3 0486-1125 TABLET, COATED 130 mg ORAL unapproved drug other 19 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6305 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6307 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6308 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6312 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 Human Prescription Drug Label 5 0942-6316 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6320 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6322 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-6326 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic Human Prescription Drug Label 4 0942-9201 SOLUTION 78 mg INTRAVENOUS NDA 2 sections
Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic Human Prescription Drug Label 4 0942-9201 SOLUTION 78 mg INTRAVENOUS NDA 2 sections
Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic Human Prescription Drug Label 4 0942-9202 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic Human Prescription Drug Label 4 0942-9202 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPD HUMAN PRESCRIPTION DRUG LABEL 4 0942-9206 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-9393 SOLUTION 155 mg INTRAVENOUS NDA 2 sections
CPDA-1 Human Prescription Drug Label 5 0942-9394 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPDA-1 Human Prescription Drug Label 5 0942-9394 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
CPDA-1 HUMAN PRESCRIPTION DRUG LABEL 5 0942-9398 SOLUTION 140 mg INTRAVENOUS NDA 2 sections
InterSol HUMAN PRESCRIPTION DRUG LABEL 5 0942-9601 SOLUTION 93 mg INTRAVENOUS NDA 13 sections